Status:
COMPLETED
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in China. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of insulin detemir or NPH-insulin given once daily at bedtime as a...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- HbA1C greater than 7.5% and less than or equal to 11.0%
- Currently on any oral antidiabetic drug (OAD) more than or equal to 3 months
Exclusion
- Previous acute treatment with insulin for more than 7 days.
- Treatment with OAD(s) which does not adhere to the approval labeling.
- Proliferate retinopathy or maculopathy that has required acute treatment within the last year.
- Known hypoglycaemia unawareness or recurrent major hypoglycaemia, that may interfere with study participation as judged by the Investigator.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT00383877
Start Date
September 1 2006
End Date
August 1 2007
Last Update
January 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China